

Human Carboxylesterase 1/CES1 Antibody

Monoclonal Mouse IgG_{2B} Clone # 544623

Catalog Number: MAB4920


DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human Carboxylesterase1/CES-1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross-reactivity wit recombinant mouse (rm) CES-3 and no cross-reactivity with rmCES-2, rmCES-5, or recombinant human CES-2 is observed.		
Source	Monoclonal Mouse IgG _{2B} Clone # 544623		
Purification	Protein A or G purified from hybridoma culture supernatant		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Carboxylesterase1/CES-1 His19-Glu563 Accession # P23141		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.		

APPLICATIONS


Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	2 μg/mL	See Below
Immunoprecipitation	25 μg/mL	Conditioned cell culture medium spiked with Recombinant Human Carboxylesterase 1/CES1 (Catalog # 4920-CE), see our available Western blot detection antibodies
Simple Western	10 μg/mL	See Below

DATA



Detection of Human Carboxylesterase 1/CES1 by Western Blot. Western blot shows lysates of human liver tissue. PVDF Membrane was probed with 2 µg/mL of Mouse Anti-Human Carboxylesterase 1/CES1 Monoclonal Antibody (Catalog # MAB4920) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for Carboxylesterase 1/CES1 at approximately 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.



Detection of Human
Carboxylesterase 1/CES1 by Simple
WesternTM. Simple Western lane view
shows lysates of human liver tissue, loaded at
0.2 mg/mL. A specific band was detected for
Carboxylesterase 1/CES1 at approximately
65 kDa (as indicated) using 10 μg/mL of
Mouse Anti-Human
Carboxylesterase 1/CES1 Monoclonal
Antibody (Catalog # MAB4920). This
experiment was conducted under reducing
conditions and using the 12-230 kDa
separation system.

PREPARATION AND STORAGE

Reconstitution Sterile PBS to a final concentration of 0.5 mg/mL.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

- 12 months from date of receipt, -20 to -70 °C as supplied
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Carboxylesterase 1 (CES-1) is a member of a large family of carboxylesterases that are responsible for the hydrolysis of ester and amide bonds (1, 2). They have broad substrate specificity ranging from small molecule esters such as phenylester to long chain fatty acid esters and thioesters. They play a major role as determinants of pharmacokinetic behavior for most therapeutic agents containing an ester. By de-esterification, they can activate or inactivate the agents. They also participate in detoxification of drugs such as cocaine and heroin in serum and liver. The resulting de-esterified metabolites are secreted out in urine. They can also detoxify organophosphate and carbamate analogues used in agrochemicals or chemical nerve agents, such as malathion, sarin, tabun, and VX. In addition to the hydrolytic activity, they can perform transesterification, a reaction important for cholesterol homeostasis. Carboxylesterase deficiency may be associated with non-Hodgkin lymphoma or B-cell lymphocytic leukemia. CES-1 shares the serine hydrolase fold observed in other esterases (3). CES-1 possesses an endoplasmic reticulum retention signal (HIEL) at its C-terminus.

References:

- 1. Redinbo, M.R. and P.M. Potter (2005) Drug Discovery Today 10:313.
- 2. Satoh, T. and M. Hosokawa (2006) Chem. Biol. Interactions 162:195.
- 3. Fleming, C.D. et al. (2007) Biochemistry 46:5603.

Rev. 2/7/2018 Page 1 of 1

